

US008674165B2

(12) **United States Patent**  
**Utterberg et al.**

(10) **Patent No.:** **US 8,674,165 B2**  
(45) **Date of Patent:** **\*Mar. 18, 2014**

(54) **ADHESIVE INJECTION SITE**  
(75) Inventors: **David S. Utterberg**, Seattle, WA (US);  
**William J. Schnell**, Libertyville, IL (US)  
(73) Assignee: **Lifestream Medical Corporation**,  
Seattle, WA (US)  
(\* ) Notice: Subject to any disclaimer, the term of this  
patent is extended or adjusted under 35  
U.S.C. 154(b) by 0 days.  
  
This patent is subject to a terminal dis-  
claimer.

3,804,094 A 4/1974 Manoussos et al.  
3,952,735 A 4/1976 Wirtschafter et al.  
3,954,109 A 5/1976 Patel  
4,053,053 A 10/1977 Tumangday  
4,123,409 A 10/1978 Kaelble  
4,182,338 A 1/1980 Stanulis  
4,224,945 A 9/1980 Cohen  
4,233,980 A 11/1980 McRae et al.  
4,336,806 A 6/1982 Eldridge, Jr.  
4,377,159 A 3/1983 Hansen  
4,675,006 A 6/1987 Hrushesky  
4,675,915 A 6/1987 Siciliano  
4,915,694 A 4/1990 Yamamoto et al.

(Continued)

(21) Appl. No.: **13/179,086**  
(22) Filed: **Jul. 8, 2011**  
(65) **Prior Publication Data**  
US 2011/0264024 A1 Oct. 27, 2011

**Related U.S. Application Data**

(62) Division of application No. 10/943,106, filed on Sep.  
16, 2004, now Pat. No. 8,017,826.  
(51) **Int. Cl.**  
**A61F 13/00** (2006.01)  
(52) **U.S. Cl.**  
USPC ..... **602/53**; 602/41; 602/42; 602/43;  
604/180  
(58) **Field of Classification Search**  
USPC ..... 602/52, 53, 41-43; 604/174, 304-308,  
604/179-180  
See application file for complete search history.

(56) **References Cited**

**U.S. PATENT DOCUMENTS**

3,367,332 A 2/1968 Groves  
3,490,448 A 1/1970 Grubb  
3,703,174 A \* 11/1972 Smith ..... 604/159

**OTHER PUBLICATIONS**

Vita Clip Brochure, 6 Pages.

(Continued)


*Primary Examiner* — Kim M Lewis

(74) *Attorney, Agent, or Firm* — Seyfarth Shaw LLP

(57) **ABSTRACT**

A pad of elastomeric material having a softness of no more than about durometer 30 Shore 00. The pad may carry adhesive for adhering the pad to a surface, either directly or indirectly through an envelope which surrounds the pad and carries the adhesive. Such a pad exhibits hemostatic and leak prevention properties against needle puncture holes in the skin or the wall of a hollow medical device. Particularly, hemostasis may be prevented with low pressure application of the pad to the skin. The pad may be previously applied to the skin of the patient or a wall of a medical device such as tubing or a solution bag, and the needle may then penetrate both the pad and the skin or medical device wall, to make a resealable puncture with leakage reduction and hemostasis when the needle is withdrawn.

**17 Claims, 3 Drawing Sheets**



(56)

**References Cited**

U.S. PATENT DOCUMENTS

4,978,342 A 12/1990 Heimreid  
 4,988,341 A 1/1991 Columbus et al.  
 5,015,228 A 5/1991 Columbus et al.  
 5,119,822 A 6/1992 Niwa  
 5,236,421 A 8/1993 Becher  
 5,259,835 A 11/1993 Clark et al.  
 5,263,965 A 11/1993 Roth  
 5,496,264 A 3/1996 Watson et al.  
 5,508,334 A 4/1996 Chen  
 5,569,207 A 10/1996 Gisselberg et al.  
 5,639,810 A 6/1997 Smith, III et al.  
 5,647,357 A 7/1997 Barnett et al.  
 5,690,610 A 11/1997 Ito et al.  
 5,728,071 A \* 3/1998 Watson et al. .... 604/180  
 5,738,641 A 4/1998 Watson et al.  
 5,810,756 A 9/1998 Montecalvo et al.  
 5,840,052 A 11/1998 Johns  
 5,891,074 A 4/1999 Cesarczyk

5,994,450 A \* 11/1999 Pearce ..... 524/505  
 6,005,159 A 12/1999 Spier  
 6,007,562 A 12/1999 Harren et al.  
 6,036,721 A 3/2000 Harren et al.  
 6,051,747 A 4/2000 Lindqvist et al.  
 6,093,468 A 7/2000 Toms et al.  
 6,117,176 A 9/2000 Chen  
 6,524,284 B1 2/2003 Marshall  
 6,582,383 B2 6/2003 Horning  
 6,932,963 B2 8/2005 Perricone  
 7,093,599 B2 8/2006 Chen  
 8,017,826 B2 \* 9/2011 Utterberg et al. .... 602/53  
 2003/0175323 A1 9/2003 Utterberg et al.  
 2006/0123664 A1 \* 6/2006 Boyd et al. .... 36/44  
 2007/0225652 A1 9/2007 Scherr

OTHER PUBLICATIONS

www.datascope.com printout, 2 Pages.  
 Rex Gauge Company, 1 page, Comparison Chart (2006).

\* cited by examiner

Fig. 1




Fig. 2




Fig. 3






Fig. 4



**Fig. 5**





1

**ADHESIVE INJECTION SITE****CROSS REFERENCE TO RELATED APPLICATION**

This application is a divisional of U.S. patent application Ser. No. 10/943,106, filed Sep. 16, 2004 now U.S. Pat. No. 8,017,826.

**BACKGROUND OF THE INVENTION**

Generally, when the needle or catheter penetrates the skin for access to an artery, a vein, or a fistula as in hemodialysis, there is a certain amount of bleeding that takes place when it is removed. In blood donation, for example, when the donor needle is removed, the donor is asked to elevate his or her arm and to press cotton gauze against the needle penetration site for some minutes, until the wound has completely clotted.

In the field of extracorporeal blood processing such as hemodialysis, larger diameter needles, such as 15 gauge needles, are used rather than the smaller needles used for blood collection and blood sampling. The blood pressure is higher due to the fistula's arterialized vein structure, and the patient is anticoagulated for the extracorporeal procedure. Thus, when the needle is withdrawn, bleeding is more pronounced, and must be dealt with more rigorously, to avoid the loss of a significant amount of blood through bleeding. Since hemodialysis in particular is performed frequently on chronic patients, even small blood losses can add up, so that it would be desirable to minimize the bleeding to avoid the relatively small amount of blood that is conventionally lost when dialysis needles are withdrawn.

Generally, compression is used for a period of time after withdrawal of any hollow bore needle, to achieve hemostasis. Typically, this is done with absorbent gauze manually pressed over the cannulation site as soon as the needle is removed. As the gauze is absorbent, this method does not staunch bleeding, but merely creates a slowing of the blood leakage so the body's natural clotting mechanisms can eventually take over and stop the blood flow. In hemodialysis, it is not uncommon to use five or six successive gauze compressions over a period of 20-30 minutes until hemostasis is achieved.

The prior art also discloses non absorbent materials to stop cannulation site bleeding. One way of accomplishing this was proposed in McRae et al. U.S. Pat. No. 4,233,980, where a pressure bladder made of flexible, non-elastic material and carried on a rigid, floor mounted arm is pressed against a site to produce hemostasis after an arterial puncture. Another way was proposed in Stanulis U.S. Pat. No. 4,182,338 where a skin contacting surface as soft as 25 Shore A durometer is part of a strap arrangement around the portion of the body where blood loss is to be prevented by compression of the skin contacting surface. Another way is Roth U.S. Pat. No. 5,263,965 which comprises a rigid disc as a manual compression aid.

Another significant problem with hollow bore needle cannulation is cannulation-induced infection to the cannulation tract and/or vessel. Although the needle is sterilized at the time of manufacture, and is maintained sterile in its package, needles may become unsterile as soon as its sterility protector is removed. At this stage it is susceptible to being contaminated by touch or air-borne bacteria. Or, the act of cannulation may drag into subcutaneous tissues bacteria from the skin surface or near-surface dermal layers. While the skin is disinfected with various chemicals, this is typically a relative rather than absolute disinfection, and bacteria will dwell on, or just under, the dead layer of skin cells of the cannulation

2

site. It is known in the field of thoracic surgery to control infection induced by scalpels and the like, by laying over the disinfected skin area intended for surgical cutting a sheet of sterile plastic. This sheet is pressed against the skin, to which it adheres without adhesive. Not only is the outer surface of the sheet a sterile field on which surgical instruments may be placed without contamination, but the sheet's adherence to the skin tends to immobilize bacteria on the skin and under the dead skin cells. Owing to the clarity of the film, it is possible for the surgeon to visualize the cutting area and cut through the film as he/she surgically cuts the patient. Thus, no or few bacteria are dragged into the surgical site during cutting due to the effect of the sterile sheet. Tegaderm is a brand name of this prior art product.

Besides cannulating patients, needles also cannulate injection sites carried on medical devices, such as tube sets, drug vials, IV bags and the like. The prior art injection sites all comprise elastomeric bungs of a hardness not less than about 10 Shore A durometer, and are carried in typically plastic housings that hold the bung fixed and under compressive forces both for sealing the space between the bung and the housing, but also to urge shut the slit caused by a cannulating needle, when removed. Many elastomers are not suitable for injection sites because they either are either cored out when cannulated with a sharp, beveled hollow bore needle, or they leak through the cannulated slit even in the presence of the compressive forces urged on it by the housing. It has not been known until now of a resealable, non-coring elastomeric material that did not require a compressive or retentive rigid housing to be effectively resealable after passage and removal of needles, including hollow bore sharp needles.

Another problem of injection sites is that they must be manufactured into the medical device. For example a dialysis set typically comprises three or more injection sites at various locations on the set. Since many sites are never used during a particular medical procedure, the cost of manufacturing injection sites in every medical device, when only a few are used, represents a great monetary waste. It would be advantageous if a simple, cheap, attachable injection site to medical devices could be developed.

**DESCRIPTION OF THE INVENTION**

This invention comprises a supersoft, elastomeric pad or sheet as an improved replacement for gauze squares, and other modes of achieving hemostasis on any bleeding site, whether by cannulation with needles of any size, or trauma from gunshot wounds and the like. Its action is the same. The pad stops the bleeding and promotes clotting.

In the case of cannulation with a needle or catheter, the pad is placed against the cannulation site either before or immediately after the cannula is removed, and improves on gauze in two major ways. First, it is not absorbent, so much less blood is lost when it is pressed against the cannulation site to seal off the cannulation slit or hole. Second, because the supersoft elastomer can sealingly conform to even the micro nooks and crannies of the skin with extremely low or even essentially no applied force, which force can be applied manually, or by tape, or any appliance alone or in combination or in serial order, the vessel underlying the cannulation site is not likely to be damaged or pressed shut. Our lab tests show that after cannulating an in vitro vascular model with a 15 g needle and maintaining the fluid pressure within the vascular model at about 80 mmHg (the pressure of a strong hemodialysis graft access), a force of over 200 gms applied to gauze squares over the (now-removed 15 G needle) cannulation site incision slows, but does not stop fluid flow out of the



cannulation site, thus mimicking clinical experience with gauze. But by using a pad of supersoft elastomer of a durometer of less than 30 Shore 0, and preferably no more than 300 Shore 00, we were able to absolutely stop flow immediately from the cannulation site with only an applied holding pressure of about 25 gms. Because of the delicate nature of fistulae and grafts, and their tendency to stenose, such reduced force and immediate cessation of bleeding is a great advance. The supersoft elastomer's conformal nature at low forces gives it great advantage as a pad, to be manually held to a cannulation site. Preferably, the pad material may be clear for direct visualization of the bleeding site underneath the pad without having to remove the pad, as is the case with the prior art. There is a risk in the prior art of removing an opaque, hemostasis appliance before full clotting is attained, causing unnecessary blood loss from the patient.

Durometer measurements made herein are in accordance with ASTM Durometer Hardness Standard D2240-03.

Preferably, the pad may be supplied sterile.

The pad may be large enough to cover any size wound. For example, in the case of gunshot wounds or military trauma, the wound may exceed many square inches in bleeding area. Blood loss from such wounds can be so rapid that bleeding must be stopped prior to evacuating a patient to a hospital. One method to do this is to pour a clotting agent directly into the wound, for example flaked chitosan. This agent soaks up blood and provides enhanced surface area for rapid clotting. However, the clotted chitosan is difficult and time consuming to remove, once the patient is in the hospital, and the clotted blood within the chitosan is not available for harvesting by any one of the known, autologous transfusion methods. It is therefore an advantage for a large wound to be covered by a sheet of the material used in this invention, as its supersoft nature conforms to the nooks and crannies of the skin and the wound boundaries, requiring little or no applied pressure to seal against blood loss, and retaining blood which may be harvested later and returned to the vascular system. Sheets or pads of this invention can be applied within the body or wound to seal off bleeding arteries or vessels directly, so as to limit or stop internal bleeding. Because the sheet is preferably clear and self-sealing, medical workers can pass medical instruments through the sheeting without removing it.

This invention relates to a particular form of elastomeric pad which may be adhered to the skin of a patient or to the exterior of a medical device (such as a tube or bag wall) at a desired cannulation site, either prior to or after the actual injection. In some embodiments, the elastomeric pad may be clear, soft and thin enough, typically on the order of 2-5 millimeters, so that the cannulation site of a patient may be palpitated through the already in-place pad prior to cannulation, in order to find an underlying vessel or medical device by touch so as to maintain the sterility of the patient's intended cannulation site. The elastomeric pad may be coated with disinfectant, or it may be applied to pre-disinfected skin, or alternatively, to a wall of a medical device such as a solution bag or tubing, before cannulation, or applied after withdrawal of the cannula to prevent bleeding without necessarily continuing applied external pressure.

Upon cannulation, an advancing needle or catheter can if desired pass first through the elastomeric pad, and then into the skin of the patient or material of the medical device, typically into a vascular system of the patient or lumen of the medical device. Upon withdrawal of the cannula, the pad exhibits the surprising property of resealing without a compressive housing, and provides significant suppression of bleeding or fluid leakage, with a consequent increase of hemostasis in a patient (or suppression of leakage from the

medical device), with significantly less need for compression to facilitate the hemostasis. Also, the cannulation site on the skin (or medical device) may be subjected to anti-microbial effect due to the presence of an antiseptic at the junction between the pad and the skin or medical device. Many suitable anti-microbial antiseptics are quite volatile, and the pad of this invention provides a physical barrier that increases the term of active disinfection by reducing the evaporation rate of the antiseptic material, such as alcohol. Bacteria on or within the skin or medical device may also be immobilized by the pad, and thus prevented from being drawn in through the skin or medical device by the advancing cannula. Thus, aseptic conditions can be promoted during the time that the cannula resides in the skin. Also, hemostasis with less or even virtually no added pressure can be achieved after withdrawal of the cannula. Then, the elastomeric pad can be removed when hemostasis has fully taken place, and when it can be expected that there will be no further spontaneous bleeding.

Thus, reduction of blood loss can be achieved, particularly in the situation of chronic patients, where access to the vascular system must take place frequently. This invention can work with fresh cannulation sites or repeat cannulation sites, commonly known as "buttonhole" sites.

An "elastomer" is defined as a rubbery material having at least one hundred percent elongation to break.

Further, in accordance with this invention, a method is provided which comprises the steps of: adhering a pad to the skin of a patient or a medical device, the pad consisting essentially of an elastomer having a hardness of no more than essentially durometer 30 Shore 0 and preferably no more than durometer 300 Shore 00.

The material of the pad preferably has a high elongation to break, typically at least about 500% or preferably about 900% to 1000% or more. Such an elastomer exhibits high resealability, so that the needle puncture hole does not readily leak blood at natural blood pressures, particularly from an artery, vein, or fistula, optionally without a compressive or retentive housing as in the prior art of injection sites carried on medical tube sets. Also, the elastomeric material, although very soft, tends to be non-coring to conventional medical needles. Thus, a stick-on injection site may be provided by this invention.

In some embodiments, the elastomer pad has a thickness of about 0.1-0.5 cm., and has a hardness of no more than about 300 Shore 00 durometer, the elastomer material being non-flowable. This is significantly softer than typical prior art medical use elastomers, for example silicone rubber elastomer which ranges from 5-50 Shore A durometer.

In some embodiments, the elastomer of this invention comprises an oil plasticized material such as an oil-plasticized block copolymer comprising (A) at least one crystalline, aryl-containing polymer segment, and (B) at least one elastomeric, aliphatic polymer segment. Some plasticized elastomers of this type are disclosed in U.S. Pat. No. 5,508,334 of John Y. Chen, and numerous other patents by the same inventor, and also in U.S. Pat. No. 5,994,450 of Tony M. Pearce, the disclosures of which are incorporated by reference herein.

In some embodiments, the crystalline, aryl-containing polymer segment comprises monoalkenylarylene polymer units such as styrene or aliphatic polymer segment may consist essentially of isoprene and butadiene polymer units in some embodiments.

The pad used in this invention may be coated on one side with a skin adhesive and directly adhered to the skin, so that preferably the exterior of the pad has no adhesive. Or an adhesive may be mixed into the material, or be a basic attribute of the tacky material. However, in other embodiments, the pad may be carried under a cloth, or a non-woven



5

fabric or plastic strip, or a length of adhesive tape as in a “Bandaid” arrangement, the elastomer pad being a replacement for the gauze pad of a “Bandaid” dressing. The strip may preferably carry a hole, thus exposing the pad, which may be transparent, where cannulation is intended. The pad may be carried in or on a single sheet or within a multi-sheet envelope, which envelope also may comprise plastic sheeting, for example, thermoplastic sheets of polyethylene, pvc, polyurethane, or similar materials, particularly when the adhesive desired is not compatible with, or does not adhere well to the elastomeric pad. The sheet or envelope carries the skin adhesive on one side thereof to adhere the pad to the skin of the patient. The pad may be at least partially melted so the material entwines with a cloth or non-woven or plastic material adhered to a strip. Preferably the pad will not detach from the skin or medical device until desired. Preferably this adherent adhesive device will prevent leakage from the cannulation site between the skin (or medical device) and the pad, when the needle has been removed.

As stated above, in some embodiments, the envelope, when used, may define a central opening to expose the pad carried therein. For example, the envelope may have a pair of opposed, major faces, with each face defining a central opening, typically aligned with each other, to expose the pad carried therein.

Some embodiments of the materials used as plasticized elastomers may comprise a high viscosity poly (styrene-ethylene-butylene-styrene) triblock copolymer having styrene end blocks and ethylene and butylene center blocks in a ratio preferably within a range of about 20:80 to about 40:60, as described in Chen U.S. Pat. No. 5,508,334, column 5. The polymer, when blended in a melt with an appropriate amount of plasticizing oil, may comprise a gelatinous elastomer composition having in some embodiments a relatively high elongation to break of at least about 1600%, and a tear resistance of at least about 500,000 dynes per square centimeter, with substantially complete, rubbery snap back when extended to about 1200% elongation, as called for in the cited Chen patent. Ultimate tensile strength may in some embodiments be at least about 800,000 dynes per square centimeter, having a low elongation set at break of substantially not greater than about two percent.

Other suitable materials are Versaflex CL2003x thermoplastic elastomer, sold by GLS Corporation of McHenry, Ill., and Dermasol DS309 of California Medical Innovations, of Pomona, Calif.

Alternatively, silicone or polyurethane formulations of the proper softness, with or without plasticizers, may be used.

Surprisingly, it has been found that many of the materials of the above-cited patents, and other soft materials, exhibit excellent and unexpected hemostatic or leak resistance characteristics when adhered to an injection location such as a patient’s skin or a medical device, with the added advantage that needle coring is suppressed by these materials, despite their softness and resealing of the needle slit despite lacking a compressive housing.

Further in accordance with this invention, a pad of elastomeric material for hemostasis may be provided, the pad having a softness of no more than about durometer 30 Shore 0. The pad further defines a pair of integral retention straps, which are made of the elastomeric material and which form one piece with the pad, being typically co-molded with the pad. The thickness of the pad is at least twice, and typically three or more times, the thickness of the retention straps.

6

As before, it is preferred for the hardness of the elastomeric material to be no more than durometer 300 Shore 00, and for the elastomer to have an elongation to break of at least about 500%.

Such a pad with straps may be used for hemostasis by wrapping the pad around the arm or leg of a patient, overlapping the retention straps along a portion of their length. As they wrap around the arm or leg, typically this overlapping takes place at a diametrically opposed area of the arm or leg from the location of the pad. Thus, the pad can be retained in position on the skin of the patient by natural tack adhesion between the retention strips. In that position, the pad may provide hemostasis to a cannulation site of a freshly withdrawn needle or catheter, and may be retained in position for as long as necessary while providing only a little degree of compression, and effecting good hemostasis while preventing bleeding from the hole in the patient’s tissue left behind by the needle or catheter. This hemostasis can even be effective to cause hemostasis in catheter access sites where connection has been made to an artery.

#### DESCRIPTION OF DRAWINGS

FIG. 1 is a perspective view of a pad of this invention.

FIG. 2 is a plan view of a pad of this invention, carried on an adhesive coated sheet of plastic.

FIG. 3 is a transverse sectional view showing the pad of this invention secured in an envelope defined by a pad of plastic sheets, which are normally peripherally secured together, but shown in separated fashion for clarity, forming an envelope which contains the pad of this invention.

FIG. 4. is a perspective view of a pad of this invention placed over a large trauma wound.

FIG. 5 is an elevational view of another embodiment of this invention, showing a pad with an integral strap.

#### DESCRIPTION OF SPECIFIC EMBODIMENTS

Referring to FIG. 1, a pad of very soft elastomer **10** is shown, having a coating of adhesive **12** on its lower face for adhesion to the skin. Pad **10** has a softness of less than durometer **30 Shore 00**, being manufactured in accordance with the teachings of Pearce U.S. Pat. No. 5,994,450, for example comprising a polystyrene-hydrogenated poly (isoprene and butadiene)-polystyrene copolymer, plasticized with either mineral oil or a combination of mineral oil and resin. Other suitable materials for manufacture of the pad of this invention are manufactured by Edizone, LC, a Utah Limited Liability Company of Pleasant Grove, Utah. Other suitable materials, for example DS309 Dermasol, are manufactured by California Medical Innovations of Pomona, Calif. Typically, the softness (hardness) of materials used for the pad **10** may be no more than durometer **25 Shore 0**, all according to tests according to the ASTM Durometer Hardness Standard D2240-03, and they may even be so soft as to not register on the Shore **00** scale and registrable only on an extremely soft scale according to a “gram bloom” test. Gram bloom involves the applied force necessary to depress a 10 mm diameter flat probe 4 mm into a sample of elastomer.

It is also sometimes desirable for the material used in this invention to have a tear strength of at least about 300,000 dynes per square cm, and an elongation to break of said elastomer of at least about 900%.

Pad **10** may be adhered to the skin **14** of a patient, after the skin has been wiped with an antiseptic such as povidone iodine or an alcohol such as isopropanol. The pad may be applied while the antiseptic is still present on the skin, so as to



trap the antiseptic against the skin. Any appropriate antiseptic may be used, and the antiseptic may be carried on or in pad 10, if desired. An increased-viscosity or gelled antiseptic may also be used, for example the antiseptic of patent Publication No. US 2003-0175323 A1.

Pad 10 may be of any desired rectangular dimension in length and width, blanket size to button size, and may be of rectangular shape, or nonrectangular shape, such as circular or oval, if desired. It may have a thickness of about 0.2-0.3 cm, which may be thin enough to feel the presence of a vein 16 through pad 10 by means of finger touch, because of the extreme softness of the elastomer material of pad 10. Then, a needle may be inserted in normal manner through pad 10 to penetrate vein 16 for a conventional IV injection process, which may include large volumes of potential solution, blood collection, or extracorporeal blood processing, with the needle penetrating pad 10 at point 18 to form a hole.

When the needle is withdrawn, point 18 recloses, and substantially reseals to prevent leakage of blood out of vein 16. Furthermore, such ultra soft material, preferably of relatively high tear resistance (tear strength) and relatively high elongation to break, is resistant to coring by an injection needle, so that the hole at point 18 recloses and reseals, optionally with gentle manual pressure, to an extent sufficient to prevent pressurized blood (or other fluid) leakage through the hole at point 18. Also, because of the adhesive attachment of pad 10, little blood leaks transversely from the puncture hole in the skin laterally between the skin and the adhering material of pad 10.

Alternatively, pad 10 may be applied immediately after withdrawing of a needle (or catheter) that penetrates the skin, such as a fistula needle, to suppress bleeding. For example, in hemodialysis and other extracorporeal blood treatment procedures, when a fistula needle is withdrawn from the patient, substantial bleeding takes place because of the larger diameter of fistula needles (and similarly with certain other extracorporeal blood flow access needles or catheters). Thus, as previously described herein, it is normal that special procedures for suppressing bleeding must take place when those needles and catheters are withdrawn. By this invention, pad 10 can be used to avoid those previously-necessary special procedures as described above, while also resulting in reduced blood loss.

The pad 10 of this invention may be of a small, button-like size of about one to six centimeters diameter or the like, particularly when it is desired to suppress the bleeding after withdrawal of a needlelike cannula, whether or not the pad is applied before penetration of the cannula, or after the cannula has been withdrawn. Also, pad 10 may be used to seal larger, laparoscopic holes in a patient, or holes which are formed in arterial walls by cardiac angiography catheters, angioplasty catheters, electronic mapping or ablation catheters, and all other medical devices which cause bleeding when they are withdrawn. A current, recommended procedure for the suppression of bleeding after the withdrawal of catheters and the like from the vascular system is pressure with the use of a sandbag for about three hours. The pad of this invention may serve as a substitute for this, being firmly applied to the resulting wound after withdrawal of a catheter, blocking bleeding, but permitting the patient to be mobile, and suppressing, or preferably completely eliminating, bleeding.

Pad 10 may be applied to the patient in any desired, conventional manner including adhesive tape, a conventional clamp, a tie around an arm or a leg, or even manually, if that is appropriate.

Furthermore if desired, pad 10 may comprise a relatively large mat or blanket of the soft elastomer material, optionally

being thicker than specific thicknesses recommended for other uses above, for example a thickness of about 0.5 cm or greater, and a length and width each of at least about 10 cm, to provide a bleeding suppression blanket, to suppress bleeding from larger wounds such as bullet and knife wounds, or other severe lacerations, providing a mode of first aid to suppress external bleeding of an injured patient. The weight of a thicker blanket of the material of this invention can provide sealing force without the need for added application of pressure, although such added pressure may of course be applied by any desired means, such as tying the pad to the patient, or the use of weights or manual pressure. Furthermore, such a form of pad 10, being of relatively greater thickness, such as a thickness of 1-5 cm. and being of pillowcase or blanket size, can be prewarmed, to provide a bleeding suppression blanket that can wrap the patient in whole or in part, and also addresses the issue of shock by providing positive warmth to the patient. Also, a hot water chamber may be provided in the pad, like a form of hot water bottle.

Also, when pad 10 is in the form of a thick blanket for bleeding suppression, it may carry an adhesive on one side for direct adhesion to the skin of the patient, with the adhesive providing further suppression of bleeding and migration of blood between pad 10 and the skin, or its natural tack may be used to retain the pad blanket 10 on the skin.

Furthermore, pad 10 in all its forms, tends to cause the clotting to take place directly in the needle track or the other injury, with the result that there are fewer bacteria in the scab which forms, and opens the possibility of less scarring.

Vitamin E oil and/or another anti-scarring agent or other medicament may be added to elastomer formulation of this invention, for release to the skin surrounding the injury, and the injury itself, such as the needle track. Also, other medicaments may be provided to the formulation of pad 10, either as a separate layer, or integrally mixed within the material of the pad itself. For example, clotting agents may be added to promote clotting, such as collagen.

The material of this invention may contain other agents as well, for example, clotting (hemostatic) agents such as collagen and other known materials, including simple, inorganic salts and other promoters for blood clotting particularly outside of the body. Other examples of possible clotting agents include: Aluminum Ammonium Sulfate, Aluminum Potassium Sulfate, Chitosan, Epinephrine, (1:50,000-1:1,000), Tannic Acid, Collagen, Styptic Collodion, Hyaluronic Acid, Sodium Hyaluronate, Aluminum Sulfate, Cotarine, Cotarine Chloride, and Cotarninium Chloride.

In some embodiments, the surface of pad 10 which faces the skin (or any other surface which is being sealed) may be glass-smooth, to promote engagement of the ultra soft pad material with irregularities in the skin or other surface, to promote sealing and to prevent the flow of blood or other fluid from the hole being sealed laterally between the pad and the skin or other surface.

Remarkably, it has been found that the materials of which pad 10 can be made as described herein generally do not need to be substantially compressed to reseal from needle sticks. Thus, while they may be used in a housing, they do not require a housing in many uses, and a housing in which they are contained does not have to hold them under compression to obtain desirable results, although such compression may be used if desired.

The shape of pad 10 of course is not limited: it may comprise a round button, or a rectangular one of diameter or other transverse dimension of one or more centimeters, or, as stated above, it may comprise a large blanket of appropriate size to address severe lacerations, and to at least partially wrap the



patient, being heated if desired to address shock while also suppressing external bleeding.

Accordingly, a stick-on injection site and/or hemostasis site is provided, which can be applied when an injection is required, and which facilitates aseptic conditions, reducing the drawing of bacteria into the body as the cannula advances through the skin, and providing good hemostasis at normal blood pressures.

Alternatively, skin **14** could be a wall of a plastic solution container, a plastic tube, or the like, with the same sealing characteristic being achieved, providing a penetrable injection site for a needle.

Turning to FIG. 2, pad **10a**, similar to pad **10**, is carried on an adhesive plastic strip **20**, with adhesive layer **22** on the underside of strip **20** permitting adherence as shown of strip **20** and pad **10a** to the skin **24** of a patient, which alternatively may comprise the wall of a solution bag, or an apertured tubing wall over which pad **10a** extends, or the like. Plastic strip **20** can carry adhesive to adhere to the skin or wall **24**. Also, the periphery **26** of pad **10a** can adhere to the same or a different kind of adhesive carried on the underside of plastic strip **20** to position pad **10a** in fixed manner covering an aperture **28** formed in plastic strip **20**.

Alternatively, FIG. 3 shows an embodiment that looks substantially identical in plan view to the embodiment of FIG. 2, in which an elastomeric pad **10b** is attached to plastic strip **20b** and retained there by a peripheral adhesive **30**. Also, an optional, additional plastic strip **32** may serve to form an enclosing envelope by a peripheral seal with plastic strip **20b**, enclosing elastomeric pad **10b**. Such seals may be peripheral seals at areas **34**. Bottom plastic strip **32** may carry an adhesive layer **36** for adhesion to the skin and an upper, peripheral adhesive layer **38** for retention and positioning of pad **10b** within the envelope **37** defined between plastic strips **20b** and **36**.

Preferably, each plastic strip defines an aperture **28b**, **40** to expose both sides of pad **10b**. Pad **10b**, carried within its envelope **37**, is exposed for finger palpitation to find a blood vessel under the skin in the case where adhesion to the skin is desired, and generally for open needle access through pad **10b** and the wall or patient's skin to which it is adhered by means of the envelope **37**.

Generally, upon withdrawal of a needle, the puncture which is formed in the respective pads **10**, **10a**, **10b** reseals without significant compression because of the unique physical characteristics of the material used as the elastomer.

A specific example of silicone material which may be used to form the pad of this invention is Rhodia 40022 reinforced silicone gel. Softer silicones than this material may also be used, if they retain the characteristics of a nonflowing elastomer.

Alternatively, pad **10** may be adhered to the skin by conventional taping, with the center of the pad left exposed for needle penetration, so that an adhesive layer **12** is not needed. The natural tack of pad **10** may provide some skin adhesion to seal against blood flow.

When the elastomeric material is plasticized with a metabolizable, lubricating oil, it may be possible to cannulate through the pads **10**, **10a**, **10b** with a non-siliconized needle, in which the needle picks up enough lubricant from the disk to desirably reduce the force of cannulation in a manner comparable with a siliconized needle, to avoid the use of siliconized needles.

As an additional feature, pads **10**, **10a**, **10b** may contain enough impregnated antiseptic such as isopropanol, so that the inner surface of the pad (at reference numeral **12**), lying against the skin, will have an alcohol content sufficient for

continuing antimicrobial effect. Alternatively, a layer of an alcohol-containing gel may be preapplied to the skin **14**, and then pad **10** may be applied to the skin and, if desired, taped in position to provide a stick-on injection site. Such alcohol-containing gels are described in Utterberg U.S. Patent Publication US 2003/0175323 A1.

Referring to FIG. 4, a patient **50** who has suffered a severe laceration **52** may be treated by immediate care personnel in the field by simply closing the laceration and covering it with an enlarged pad **10c** made in accordance with this invention. Pad **10c** may comprise a soft, transparent elastomer material as described above. A specific material used for pad **10c** may be Dermasol DS309, comprising a styrene-ethylene/butylene-styrene copolymer which carries more than 50% of mineral oil as a plasticizer. The DS309 material has a durometer of 200 Shore 00 and an ultimate elongation (elongation to break) of about 1,000%, and a tensile strength of 800-1200 psi. A material that may be used for pad **10c** (and other pads in accordance with this invention) may comprise 15-20% of styrene-ethylene/butylene-styrene copolymer; 80-85% of mineral oil USP; 0.1-0.3% of antioxidant; and 4 parts per million of Vitamin E, this being a formulation published for Dermasol by California Medical Innovations.

Pad **10c** may be of any appropriate shape or size, and may have any desired thickness, for example, from 0.2 cm. to 1 cm. Pad **10c** has a natural tack so that, if desired, it can spontaneously be retained over the wound site **52**. Alternatively, it may be held by tape or straps, as desired, to hold blood in the wound site and to promote hemostasis (clotting). If desired, a hemostasis (clotting) agent as described above may be applied, or such a hemostasis agent may be carried as a layer on the inner face of pad **10c**, or may be an ingredient in the elastomer formulation of pad **10c** to leak out into the wound to promote clotting.

Referring to FIG. 5, a pad **56** is shown, being made of an elastomeric material in accordance with this invention, such as Dermasol DS309, and further defining a pair of integral retention straps **58**, **60** which are made of the same elastomeric material and which form one piece with the pad, having been preferably molded with the pad in a single step. The thickness of the pad **56** can be seen in this embodiment to be about five or six times greater than the thickness of the retention straps. Pad **56**, with integral straps **58**, **60**, may be carried on a relatively stiff backing strip **62** for storage, from which it may be removed for use.

This pad may be used by being placed on an arm or leg of the patient over a needle or catheter injection site, before or after insertion and withdrawal of the needle or a catheter introducer device. Then, after withdrawal of the needle or catheter, pad **56** can reseal, to facilitate hemostasis, and also it prevents blood leakage.

Pad **56** can be attached by stretching the straps **58**, **60** around the arm or leg of the patient, causing portions of the straps to overlap, typically at a diametrically opposed portion of the arm or leg from the position of the pad on the skin. The natural, adhesive tack of the straps can provide desired adhesion to each other, holding the pad in place on the arm or leg without added adhesive. Alternatively, an adhesive or other technique may be used to hold the straps in position.

Thus, a stick-on injection site or hemostasis device is provided, in which the pad through which injection may be made, if desired, does not have to be retained under compression in a housing to obtain good resealing. Accordingly, the pad-type injection site or hemostasis device does not require a rigid housing to hold it in a compressed state, but the pad simply provides spontaneous resealing under most physiological blood pressure conditions, thus greatly reducing loss of



## 11

blood. Such a pad type injection site is also usable to provide an injection site through a wall of a medical device, while providing good resealing after the needle is withdrawn. Also, typically larger pads of this invention may be used for hemostasis of larger wounds.

The above has been offered for illustrative purposes only, and is not intended to limit the scope of the invention of this application, which is as defined in the claims below.

That which is claimed is:

1. A method for suppressing leakage from a wall of a leakable object after removal of a needle from the wall comprising:

coupling a pad to the wall, the pad consisting essentially of an elastomer having a hardness of no more than about durometer 30 Shore 0;

passing the needle through the pad and the wall, thereby forming a hole in the wall; and  
withdrawing the needle from the wall and the pad, wherein the pad suppresses leakage from the hole.

2. The method of claim 1 wherein the pad has a thickness of no more than 0.5 cm.

3. The method of claim 1 further comprising disposing the pad in an envelope having an adhesive on a side thereof adapted to removably couple the pad to the wall.

4. The method of claim 3 wherein the envelope defines a central opening to expose the pad disposed therein.

5. The method of claim 3 wherein the envelope includes a pair of opposing, major faces defining a central opening to expose the pad disposed therein.

6. The method of claim 1 wherein the pad is substantially free of a compression-providing housing.

7. The method of claim 1 wherein the pad has a thickness of greater than 0.5 cm.

8. The method of claim 1 wherein the pad has a smooth face in contact with the wall.

9. The method of claim 1 wherein the elastomer has an elongation to break of at least 500 percent.

10. The method of claim 1 wherein the pad is substantially free of compression.

## 12

11. The method of claim 1, wherein the leakable object is a patient and the wall is skin of the patient.

12. A method for suppressing leakage from skin of a patient after removal of a needle from the skin, comprising:

coupling a pad to the skin, the pad consisting essentially of an elastomer having a hardness of no more than about durometer 30 Shore 0;

passing a needle through the pad and the skin, thereby forming a hole in the skin; and

withdrawing the needle from the skin and the pad, wherein the pad suppresses leakage from the hole.

13. A medical apparatus for suppressing bleeding or leakage comprising:

a pad consisting of elastomeric material for homeostasis, the pad having a hardness of no more than about durometer 30 Shore 0; and

a strap integral with the pad and made of the elastomeric material.

14. The medical apparatus of claim 13 wherein the elastomeric material has an elongation to break of at least 500 percent.

15. The medical apparatus of claim 13 wherein the pad has a thickness at least three times a thickness of the retention straps.

16. The medical apparatus of claim 13 wherein the pad is substantially transparent.

17. A method of suppressing bleeding or leakage, from skin of a patient comprising:

providing a pad consisting of elastomeric material for homeostasis, the pad having a hardness of no more than about durometer 30 Shore 0; and

a strap integral with the pad and made of the elastomeric material

applying the medical apparatus around a needle insertion site of the skin and

overlapping the strap along at least part of a length of the strap, thereby retaining the pad on the needle insertion site.

\* \* \* \* \*